An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old (MACS2163)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01724138 |
|
Recruitment Status :
Withdrawn
First Posted : November 9, 2012
Last Update Posted : April 20, 2017
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
To characterize the PK of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old, when administrated with a fixed starting dose of 20 mg/kg/day.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| β-thalassemia Major | Drug: Deferasirox | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old |
| Study Start Date : | June 2013 |
| Estimated Primary Completion Date : | April 2014 |
| Estimated Study Completion Date : | October 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Beta thalassemia
Drug Information available for:
Deferasirox
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Deferasirox
The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to <6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
|
Drug: Deferasirox
Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. |
Primary Outcome Measures :
- the PK profile of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old. [ Time Frame: PK sampling times are 0.5, 2.5, 6, 10h in Day 1 postdose; Day 2, 3, 4 and 5 predose and 0.5, 2.5, 6, 10h post dose on Day 4, then pre-dose at each subsequent visit until Week 49. Day -1 PK sample will be treated as Day 1 predose sample. ]Area under the plasma concentration-time curve from time zero to the end of the dosing interval.
- the PK profile of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old: Cmax [ Time Frame: PK sampling times are 0.5, 2.5, 6, 10h in Day 1 postdose; Day 2, 3, 4 and 5 predose and 0.5, 2.5, 6, 10h post dose on Day 4, then pre-dose at each subsequent visit until Week 49. Day -1 PK sample will be treated as Day 1 predose sample. ]The maximum plasma concentration of study medication.
- the PK profile of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old: Tmax [ Time Frame: PK sampling times are 0.5, 2.5, 6, 10h in Day 1 postdose; Day 2, 3, 4 and 5 predose and 0.5, 2.5, 6, 10h post dose on Day 4, then pre-dose at each subsequent visit until Week 49. Day -1 PK sample will be treated as Day 1 predose sample. ]Tmax was directly determined from the raw plasma concentration-time data.
Secondary Outcome Measures :
- The safety and tolerability of deferasirox following multiple dosing in pediatric β-thalassemia major patients. [ Time Frame: Baseline, every 4 weeks until 48 weeks after taking the drug ]The adverse events and abnormal measurements of hematology, blood chemistry, urinalysis, urinary protein/creatinine ratio, physical examination, auditory and ocular examinations, ECG, ECHO, and growth development are collected for the measurement of safety and tolerability.
- The efficacy of deferasirox in pediatric β-thalassemia patients as measured by change of serum ferritin. [ Time Frame: Baseline, every 4 weeks until 48 weeks after taking the drug ]Changes in serum ferritin from baseline to every 4 weeks are collected for the measurement of efficacy.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 71 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pediatric patients aged from 2 to less than 6 years old.
- Patients with transfusion dependent β-thalassemia major.
- Serum ferritin values ≥ 1000 ng/ml at screening.
- Written informed consent must be obtained from the patient's legal guardian in accordance with local law and regulation prior to any screening procedures.
Exclusion Criteria:
- Non-transfusion-dependent thalassemia.
- Systemic diseases which would prevent study treatment (e.g. uncontrolled hypertension, cardiovascular, renal, hepatic, metabolic, etc.)
- Serum creatinine > age adjusted ULN.
- Significant proteinuria as indicated by a urinary protein/creatinine ratio (UPCR) ≥ 0.5mg/mg in a non-first void urine sample at screening. If UPCR is found to be ≥ 0.5 mg/mg the test can be repeated after 1 month.
- ALT/AST > 2.5xULN and total bilirubin > 1×ULN.
- Left ventricular ejection fraction < 56% by echocardiography.
- Patient has a known history of HIV seropositivity or history of active/treated hepatitis B or C (a test for screening is not required).
- A history of clinically relevant ocular and/or auditory toxicity related to iron chelation therapy
- Any surgical or medical conditions which will significantly alter the absorption, distribution, metabolism or excretion of the drug(e.g. ulcerative disease, uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach and/or small bowel resection).
- Other conditions which investigator deems potential harm to patients if participate the study.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01724138
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01724138 |
| Other Study ID Numbers: |
CICL670ACN02 |
| First Posted: | November 9, 2012 Key Record Dates |
| Last Update Posted: | April 20, 2017 |
| Last Verified: | August 2014 |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
deferasirox |
Additional relevant MeSH terms:
|
Thalassemia beta-Thalassemia Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies |
Genetic Diseases, Inborn Deferasirox Iron Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action |